摘要:
PDE4 inhibition is achieved by novel compounds, e.g., N-substituted diarylamine analogs. The compounds of the present invention are of Formula I: wherein A, B, D, R1, R2, R3 and R4 are as defined herein.
摘要:
PDE4 inhibition is achieved by novel compounds, e.g., N-substituted diarylamine analogs. The compounds of the present invention are of Formulas I-III: wherein A, B, D, E, G, J, K, R1, R2, R3, R4, R11, R12, R13, R14, R21, R22, R23 and R24 are as defined herein.
摘要翻译:PDE4抑制通过新化合物,例如N-取代的二芳基胺类似物来实现。 本发明的化合物为式I-III:其中A,B,D,E,G,J,K,R 1,R 2, R 3,R 4,R 11,R 12,R 13,R 13, SEQ ID NO:14,R 21,R 22,R 23和R 24定义如上 这里。
摘要:
Compounds of the formula I: wherein m, n, p, X, Ar, R1, R2, R3, R4 and R5 are as defined herein. Methods of making the compounds and using the compounds for treatment of 5-HT6 receptor-mediated diseases are disclosed.
摘要:
This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: wherein Z is —C(O)— or —S(O)2—, X is carbon or nitrogen, Y is carbon, and X-Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.